Coherus Marks Exit From Biosimilars By Completing Udenyca Divestment
Accord BioPharma Takes Charge Of Pegfilgrastim Franchise In US
Coherus has officially marked its exit from biosimilars by completing the divestment of its Udenyca pegfilgrastim franchise. Meanwhile, buyer Accord BioPharma has set out how it expects to benefit not only from a growing asset but also from the Coherus personnel that have moved over.
